Abstract
Metal complexes that hydrolyze DNA are important, due to their potential use as therapeutic agents, tools in elucidating oligonucleotide structure, and models for naturally-occurring metalloprotein nucleases. Therefore, this review focuses on recent advances in the hydrolysis of DNA and phosphate diester model compounds by non-lanthanide metal complexes.
Keywords: Mononuclear Cobalt Complexes, DNA cleavage, Zinc Complexes, Transition Metal, Dinuclear Iron
Current Organic Chemistry
Title: Hydrolytic DNA Cleavage by Non-Lanthanide Metal Complexes
Volume: 11 Issue: 17
Author(s): Thomas A. Shell and Debra L. Mohler
Affiliation:
Keywords: Mononuclear Cobalt Complexes, DNA cleavage, Zinc Complexes, Transition Metal, Dinuclear Iron
Abstract: Metal complexes that hydrolyze DNA are important, due to their potential use as therapeutic agents, tools in elucidating oligonucleotide structure, and models for naturally-occurring metalloprotein nucleases. Therefore, this review focuses on recent advances in the hydrolysis of DNA and phosphate diester model compounds by non-lanthanide metal complexes.
Export Options
About this article
Cite this article as:
Shell A. Thomas and Mohler L. Debra, Hydrolytic DNA Cleavage by Non-Lanthanide Metal Complexes, Current Organic Chemistry 2007; 11 (17) . https://dx.doi.org/10.2174/138527207782418654
DOI https://dx.doi.org/10.2174/138527207782418654 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dual Roles of Sulforaphane in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Prospects for Plant-Derived Chemopreventive Agents Exhibiting Multiple Mechanisms of Action
Current Medicinal Chemistry - Anti-Cancer Agents Dinuclear Berenil-Platinum (II) Complexes as Modulators of Apoptosis in Human MCF-7 and MDA-MB231 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cetuximab and the Head and Neck Squamous Cell Cancer
Current Topics in Medicinal Chemistry Role of FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands
Current Drug Discovery Technologies Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma
Current Medicinal Chemistry Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Syntheses and Preliminary Evaluation of Dual Target PET Probe [<sup>18</sup>F]-NOTA-Gly3- E (2PEG4-RGD-WH701) for PET Imaging of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Development of RNA Aptamer-Based Therapeutic Agents
Current Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Tumor Initiating Cells
Current Pharmaceutical Biotechnology Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets Pharmacophore Modeling and 3D QSAR Studies of Novel Human Carbonic Anhydrase IX Inhibitors
Letters in Drug Design & Discovery Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
Current Genomics Detection of Tumor Markers with ProteinChip® Technology
Current Pharmaceutical Biotechnology Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design